DNA vaccines: safety and efficacy issues
Springer Seminars in Immunopathology · 1997 · 19 (2) · 245-256
DOI: 10.1007/bf00870272 ↗At a glance
Vergleichsstudie in Springer Seminars in Immunopathology, 1997. Written by D M Klinman and 6 co-authors. Institution: Section of Retroviral Immunology, Food and Drug Administration, Bethesda, MD 20892, USA. Cited 72 times so far (Crossref); 56 references.
Abstract (original language)
DNA technology has been harnessed to produce a variety of plasmid-based vaccines designed to prevent viral, bacterial and parasitic infections. The rapid adoption and implementation of this novel vaccine strategy carries with it important safety and efficacy concerns. This review will focus on whether DNA vaccines (1) are likely to induce systemic or organ-specific autoimmune disease, (2) have the potential to induce tolerance rather than immunity, and (3) are as effective in individuals with depressed immune function as they are in healthy adults.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Section of Retroviral Immunology, Food and Drug Administration, Bethesda, MD 20892, USA.
Cite
APA
Klinman, D. M., Takeno, M., Ichino, M., Gu, M., Yamshchikov, G., Mor, G., & Conover, J. (1997). DNA vaccines: safety and efficacy issues. Springer Seminars in Immunopathology, 19(2), 245-256. https://doi.org/10.1007/bf00870272
Vancouver
Klinman DM, Takeno M, Ichino M, Gu M, Yamshchikov G, Mor G, et al. DNA vaccines: safety and efficacy issues. Springer Seminars in Immunopathology. 1997;19(2):245-256. doi:10.1007/bf00870272
BibTeX
@article{Klinman1997,
author = {Klinman, D M and Takeno, M and Ichino, M and Gu, M and Yamshchikov, G and Mor, G and Conover, J},
title = {DNA vaccines: safety and efficacy issues},
journal = {Springer Seminars in Immunopathology},
year = {1997},
volume = {19},
number = {2},
pages = {245--256},
doi = {10.1007/bf00870272}
}
EUVIMED